{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088821","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.887984+00:00","generated_at":"2026-06-12T01:27:47.339492+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Iovance reports Q2 2023 net loss $106.5M, cash $317.3M; lifileucel PDUFA Nov 25","bullets":["FDA set PDUFA date Nov 25, 2023 for lifileucel BLA in advanced melanoma under priority review.","Cash $317.3M at June 30; raised ~$161.4M from July public offering; expects funding into end of 2024.","Q2 2023 net loss $106.5M ($0.47/sh) vs $99.3M ($0.63/sh) in Q2 2022; R&D expense up to $86.3M.","Revenue $0.2M from Proleukin acquisition in May 2023; no revenue in prior-year period.","Registrational NSCLC trial IOV-LUN-202: 26.1% ORR in preliminary analysis; enrollment continuing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088821","json":"https://secwatch.observer/filing/0001104659-23-088821.json","markdown":"https://secwatch.observer/filing/0001104659-23-088821.md","text":"https://secwatch.observer/filing/0001104659-23-088821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923088821/0001104659-23-088821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923088821/tm2323093d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:27:47.339492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c49e4e7ee47a9da26453dbcd44f99879b9d1b677","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported financial results for second quarter and first half 2023.","evidence_excerpt":"On August 8, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and an update on recent developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923088821/0001104659-23-088821-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter and first half 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}